RE: Re: DPP IV in EnzymAid

[Guest guest]

,

I would like to clarify the issue that has been raised regarding the

presence of Dipeptidyl peptidase IV (DPP-IV) in the EnZymAid formulation.

EnZymAid DOES contain DPP-IV in the proprietary enzyme blend called

Caso-glutenase which is comprised of peptidase enzymes with documented

DPP-IV activity, specifically targeting the breakdown of casomorphin and

gluteomorphin peptides. According to Mark Brudnak. Ph.D., N.D. " the

Caso-glutenase is a peptidase concentrate providing assistance with exorphin

digestion and containing both high exo-peptidase as well as endo-peptidase

activity. " The overall activity of this blend is one of the most

comprehensive and higher then other single peptidases or proteases

available. The use of the genomeceutical Galactose, in this formulation, is

proposed to provides additional activity in increasing the expression as

well as the amount of DPP-IV. The combined activity of both the DPP-IV

containing peptidase and the Galactose are of major interest as we look to

further evaluate and study the impact of these substances in those with

enzyme deficiencies.

For your interest I would like to share with you the results of Pilot Study

on the EnZymAid formulation, completed at the end of 2000, in children

diagnosed with autism spectrum disorders. This study, co-sponsored by the

Autism Research Institute (ARI) and conducted by five medical practitioners

treating autistic children, was a parent judged study. All evaluation forms

went to the ARI offices for the development of the study database. Over the

coarse of a 12-week period of time the participating children were evaluated

utilizing 13 different parameters of function and behavior. The results of

this pilot study were impressive and have drawn interest by a major

University and Medical Center to undertake further extensive studies with

these enzymes. Additionally a scientific paper, providing details of this

clinical trial, has been submitted for publication in a Medical Journal.

SUMMARY OF THE DATABASE:

Following is a graph providing the percentage of families that reported a

moderate, significant and/or great improvement rating in symptoms over a 12

week time period.

WEEK 1-2 WEEK 3-4 WEEK 5-6 WEEK 7-8 WEEK 9-10 WEEK 11-12

Eye Contact 37% 47% 43% 56% 67% 67%

Socialization 42% 67% 71% 76% 81% 90%

Attention 40% 54% 63% 59% 73% 68%

Mood 36% 52% 57% 60% 55% 59%

Hyperactivity 31% 31% 50% 75% 75% 80%

Anxiety/Compulsions 20% 41% 46% 47% 41% 60%

Stimming 27% 38% 27% 38% 31% 50%

Comprehension 40% 45% 58% 55% 50% 63%

Speech/language 27% 41% 53% 47% 38% 44%

Sound Sensitivity 17% 17% 18% 42% 25% 50%

Digestion 35% 50% 56% 50% 56% 50%

Sleep 23% 36% 43% 50% 64% 57%

Perseveration 33% 38% 44% 50% 39% 53%

Improvement Ratings: 0 = None

1 = Possible

2 = Moderate

3 = Significant

4 = Great

The observations from this study suggest that EnZymAid can be effectively

used to provide quite noticeable measures of improvement in function and

behavior of those children on the autism spectrum. This study provides

compelling support for the use of this formulation as a digestive aid in

children with autism spectrum disorders. Additionally the response by

families to the combined use of EnZymAid and the multi-spectrum enzyme

formulation, EnZym-Complete, has provided great encouragement and a desire

to further study the role of these unique enzymes in the health and

functioning of those with autism.

Thank you for allowing me to share this information. The role of digestive

enzymes will continue to be an important area of study for Kirkman

Laboratories. We certainly support the effort of all those who are dedicated

to help provide products and services to meet the needs of families who have

children diagnosed with the full range of autism spectrum disorders.

Ilene

[ ] Re: DPP IV in EnzymAid

EnzymAid does not contain any DPP IV - the pepsidase that directly

works on the casein/gluten derivatives. It contains galactose which

works in the following way. This information is from the Kirkman

website:

" Galactose appears to be able to increase the expression of the

Dipeptidylpeptidase IV (DPIV) gene. This means adding galactose can

increase the amount of DPIV that is present. Now, if in autistics the

situation is not that there is absolutely zero DPIV, but rather that

the gene has been silenced or " turned down " (down-regulated), then

the addition of galactose has the potential to reverse or circumvent

that. The caveat being that the gene needs to at least be functional. "

.

> Is this a new formulation? I thought EnZymAid did not contain the

DPP

> IV enzyme which is specific to the breakdown of the casein peptides.

> Thank you.

> .

>

> >(the high peptidase, DPP-IV and genomeceutical enzyme)